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doi:10.1Objective: Home surveillance monitoring might identify patients at risk for interstage death after stage 1 pal-
liation for hypoplastic left heart syndrome. We sought to identify the effect that a high-risk program might have
on interstage mortality and identification of residual/recurrent lesions after neonatal palliative operations.
Methods: Between January 2006 to January 2010, newborns after stage 1 palliation for hypoplastic left heart
syndrome or shunt placement were invited to participate in our high-risk program. Patients enrolled in our
high-risk program comprise the study group. Patients who had similar operations between January 2002 and De-
cember 2005 comprise the control group. Comparisons are made between the 2 groups with respect to interstage
mortality and the frequency and timing of interstage admissions requiringmedical, catheter, or surgical treatment.
Results: Seventy-two patients met the criteria for our high-risk program. Fifty-nine (82%) of 72 patients were
enrolled. Among 19 patients with hypoplastic left heart syndrome in our high-risk program, outpatient interstage
mortality was zero. Outpatient interstage mortality for the 36 control subjects with hypoplastic left heart syn-
drome was 6%. Among 40 patients with shunts in the study group, there was 1 outpatient interstage death com-
pared with 4 (6%) deaths in 68 subjects in the control group. Significant residual/recurrent lesions were
identified with similar frequency between the 2 groups. However, after shunt operations, these lesions were de-
tected and treated at significantly younger mean ages for patients followed in the high-risk program (P<.005).
Conclusions: Initiation of a high-risk program might decrease interstage mortality after high-risk neonatal pal-
liative operations. Such an approach might contribute to earlier detection of significant residual/recurrent lesions
amenable to therapy. (J Thorac Cardiovasc Surg 2011;142:855-60)C
H
DSurvival to discharge has significantly improved after stage
1 palliation (S1P) for infants born with hypoplastic left heart
syndrome (HLHS); however, interstage mortality remains
an important problem, with 10% to 15% interstage attrition
reported.1-5 Recently, implementation of home surveillance
monitoring (HSM), which is the use of home pulse oximetry
and daily weights, has been reported to result in improved
identification of patients at risk, thereby allowing for early
surgical or catheter intervention.6 We hypothesized that
other neonates who undergo palliative surgical procedures
might benefit from such monitoring. Additionally, we be-
lieved that the formation of a high-risk program designed
specifically to closelymonitor, track, and treat these patients
might offer improved detection of important residual/recur-
rent lesions and thereby contribute to improved interstage
survival.
The purpose of this report is to describe our experience
with this approach since its inception at our center. Our cen-e Congenital Heart Institute at Miami Children’s Hospital and Arnold Palmer
ren’s Hospital, Miami, Fla.
ures: Authors have nothing to disclose with regard to commercial support.
d for publication Sept 15, 2010; revisions received Dec 16, 2010; accepted for
cation Jan 25, 2011; available ahead of print March 14, 2011.
for reprints: Nancy C. Dobrolet, MD, Miami Children’s Hospital, Cardiol-
200 SW 60th Court, Miami, FL 33155 (E-mail: nancy.dobrolet@mch.com).
23/$36.00
ht  2011 by The American Association for Thoracic Surgery
016/j.jtcvs.2011.01.054
The Journal of Thoracic and Cater is unique in that it is located in a tertiary care children’s
hospital with no birthing center or affiliation with any
neonatal units. Therefore there are no live births at our insti-
tution, and our patients are 100% referred from outside
cardiology groups with no formal affiliation with our
hospital.
Before the initiation of our high-risk program, all inter-
stage care was provided by the individual referring cardiol-
ogy groups. Typically, the patient would not return for
evaluation by our cardiac team until the time of the pre–
stage 2 (S2) catheterization or in the event of an interstage
admission.MATERIALS AND METHODS
Patient Selection/Inclusion
Beginning in January 2006, a high-risk programwas formed (see below)
at our tertiary care institution for the express purpose of providing system-
atic, closely monitored care of infants believed to be at high risk after pal-
liative neonatal procedures. Our high-risk programwas designed to include
a high-risk outpatient clinic coupled with HSM. Enrollment in the program
was offered to those families whose infants underwent S1P for HLHS or
HLHS variants or placement of a Blalock–Taussig (BT) or central shunt
with or without a Damus–Kaye–Stansel (DKS) shunt.
To identify a control group, we performed a retrospective review of all
infants with similar anatomic diagnoses who underwent similar operations
during the previous 4 years (January 2002–December 2005). Interstage
care varied for these patients, depending on the practice of the different
referring cardiology groups.rdiovascular Surgery c Volume 142, Number 4 855
FIGURE 1. Example of printed material for the family of a patient with
HLHS.
FIGURE 2. Materials provided to families at discharge
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HLHS ¼ hypoplastic left heart syndrome
HSM ¼ home surveillance monitoring
S1P ¼ stage 1 palliation
S2 ¼ stage 2
S2P ¼ stage 2 palliation
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DPatients’ records were carefully reviewed for the occurrence of un-
planned interstage hospital admissions requiring (1) inotropic support, (2)
catheter-based interventions to alleviate recurrent/residual lesions, (3) surgi-
cal intervention to alleviate recurrent/residual lesions and early progression
to stage 2 palliation (S2P), or (4) need for cardiopulmonary bypass support.
Patients after S1P for HLHS or shunt placement with or without a DKS
shunt were deemed at high risk for interstage morbidity and mortality. In
January 2006, we began to follow these patients in our high-risk program,
which included a high-risk outpatient clinic visit and HSM. The details of
our high-risk program are described below. Wewere able to compare inter-
stage mortality and interstage admissions requiring interventions for
patients before and after the inception of our high-risk program.
This study was approved by the institutional review board. The same
surgeons performed all operations during the 2 time periods using similar
techniques, and patients in both groups were discharged on 20 mg/d oral
aspirin.
Home Surveillance Monitoring
Similar to other approaches for discharging high-risk neonates,7 each
patient was discharged after detailed parental education related to symp-
toms and signs to monitor and written guidelines instructing when to con-
tact their private cardiologist and the high-risk team. Families were
instructed to measure and record daily oxygen saturations and daily
weights using their home pulse oximeter and digital scale. Parents were
also instructed on the preparation of a 24 calories per ounce formula. Re-
portable signs for parents thought to relate to compromise in cardiopulmo-
nary or nutritional status are shown in Figure 1. Parents were supplied with
a medical passport, which listed their infant’s anatomy and surgical proce-
dures and expected oxygen saturation level. Printed materials supplied to
each family at the time of discharge are listed in Figure 2. Each referral pe-
diatrician and cardiologist was contacted by means of fax and telephone to
review the plan of care, reportable symptoms, and resources available for
consultation 24 hours per day.
The high-risk cardiac nurse practitioner contacted families by telephone
every other week or more frequently if the infant had issues to review home
monitoring data, weight gain, formula preparation, access to their primary
cardiologist and pediatrician, general development, medication administra-
tion, and follow-up with specialty physicians, if indicated. In addition, at-
tention was given to the identification of any pending insurance coverage
issues. Our electronic medical record, I-Rounds (Teges, Coral Gables,
Fla), was used to track all telephone conversations. Patients participating
in the high-risk program were flagged for easy identification and follow-
up. Electronic high-risk progress notes were entered by the cardiac nurse
practitioner after all telephone communications with families, primary pe-
diatricians/cardiologists, or both. These notes typically contained the home
oxygen saturation levels and weight gain data and could be reviewed at any
time by any member of our cardiac team.856 The Journal of Thoracic and Cardiovascular SurgHigh-Risk Outpatient Clinic
All outpatient encounters took place at the Congenital Heart Institute at
Miami Children’s Hospital. Before discharge, families were scheduled to
return to our institution for their first high-risk appointment 1 month after
discharge (Figure 3). Our clinic did not replace regularly scheduled visits
with the primary cardiologist. Our high-risk team included an intensive
care cardiologist and cardiac nurse practitioner, who evaluated all patients
enrolled in the program. This outpatient encounter included a sedated echo-
cardiogram, chest radiograph, electrocardiogram, and physical examina-
tion by the high-risk team. If at the time of discharge the pulmonary
artery anatomy was of potential concern, quantitative nuclear medicine
lung perfusion scans were performed as well. The clinic evaluation in-
cluded meticulous review of all medication and formula preparation and
administration. Home monitoring data were reviewed with the parents.
All echocardiograms performed in the high-risk clinic were interpreted
by our Congenital Heart Institute echocardiographers.ery c October 2011
FIGURE 3. Example of a high-risk clinic appointment card.






AAwith MS or MA 13 20
AS with MS or MA 4 7
HLHS with VSD 1 7
HLHS with intact atrial septum 1 0
HLHS with TAPVC 0 2
Shunt 40 68
With DKS shunt
DORV with subAS 2 3
Unbalanced AVC 0 2
Interrupted aortic arch, VSD 1 3
Shone-type complex 3 1
TGA variant 3 3
DILV 1 2
Without DKS shunt
Pulmonary atresia, VSD 8 12
Pulmonary atresia, IVS 8 11
Heterotaxy 6 12
Ventricular inversion 0 3
Tricuspid atresia 6 7
Unbalanced AVC 0 1
Truncus arteriosus, IAA 0 1
TOF/DORV variants 3 5
Interrupted aortic arch, VSD 0 2
DILV 1 0
S1P, Stage 1 palliation; HLHS, hypoplastic left heart syndrome; AA, aortic atresia;
MS, mitral stenosis; MA, mitral atresia; AS, aortic stenosis; VSD, ventricular septal
defect; TAPVC, total anomalous pulmonary venous connection; DKS, Damus–
Kaye–Stansel; DORV, double-outlet right ventricle; AVC, atrioventricular canal;
TGA, transposition of the great arteries; DILV, double-inlet left ventricle; IVS, intact
ventricular septum; IAA, interrupted aortic arch; TOF, tetralogy of Fallot; Shone-type
complex, multiple left-sided hypoplastic lesions not amenable to 2-ventricle repair.








Sex (male) 73% 57% NS
Birth weight (kg) 3.2  0.1 3.2  0.1 NS
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coursewas progressing as expected. If therewere no problems detected, pa-
tients were scheduled for their pre-S2 catheterization. For our patients with
HLHS, this was between 3 and 4 months of age. The second palliative op-
eration was scheduled soon after completion of the pre-S2 catheterization,
typically by 4½months of age for patients with HLHS. HSM continued un-
til the time of the second palliative operation.
If during the high-risk visit a recurrent/residual lesion was suspected,
the patient was scheduled for further evaluation, usually cardiac catheteri-
zation. If a significant decrease in cardiac function was detected, the patient
was directly admitted to the cardiac intensive care unit for further evalua-
tion, treatment, and intervention when indicated. In selected cases addi-
tional high-risk clinic appointments were scheduled for follow-up of
a mild residual lesion or as follow-up to an interstage intervention.
Statistical Analysis
Our prospective sequel server database, I-Rounds, was used for data col-
lection. The database allows for identification of all palliated patients with
congenital heart disease and provides a review of all hospital admissions,
interstage interventions/operations, and mortality data.
The Statistical Package for Social Sciences (PASW 18; SPSS, Inc, Chi-
cago, Ill) was used to organize, validate, and analyze the collected data. In-
dicators of central tendency and dispersion (medians, means, standard
deviations, standard errors of the mean, and 95% confident intervals)
were estimated for quantitative variables, whereas frequencies and percent-
ages were used for qualitative variables. The Mann–Whitney U test was
selected to compare median values between groups. We also used the c2
test or Fisher’s exact test when appropriate to identify differences between
proportions or associations between categorical variables. Tables were con-
structed to present the most relevant findings.
Age at operation (d) 5  1 12  2 <.05
Length of stay (d) 34  5 30  3 NS
Perfusion time (min) 219  7 243  8 NS
DHCA (min) 18.6  1.8 17.9  2.6 NS
Shunts
Sex (male) 55% 52% NS
Birth weight (kg) 3.2  0.2 3.3  0.1 NS
Median age at operation (d) 4 (0–37) 6 (1–67) NSRESULTS
The study group consisted of 59 patients followed in our
high-risk program. Control subjects consisted of 104
patients before the inception of our high-risk program.
The patients’ diagnoses are listed in Table 1. The operative
characteristics are listed in Table 2.Length of stay (d) 33  4 33  5 NS
Variables are reported as means standard errors of the mean unless otherwise noted.
S1P, Stage 1 palliation; HLHS, hypoplastic left heart syndrome; NS, not statistically
significant; DHCA, deep hypothermic circulatory arrest.Interstage Mortality
Formore information on interstage mortality, see Table 3.The Journal of Thoracic and CaStudy group. S1P for HLHS. No patients in our high-risk
program have died at home after S1P for HLHS. One patient
died in the hospital after readmission for methicillin-resistantrdiovascular Surgery c Volume 142, Number 4 857














S1P 26 25 (96%) 19 (76%) 0 1 (5%) 0
Shunts 53 47 (89%) 40 (85%) 1 (3%) 0 0
Control group
S1P 43 36 (84%) — 2 (6%) 2 (6%) 0
Shunts 74 68 (92%) — 4 (6%) 0 0
S2P, Stage 2 palliation; S1P, stage 1 palliation. *Not significant.
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DStaphylococcus aureus–induced endocarditis with resultant
shunt thrombosis.
Shunts. There was 1 outpatient death in an international pa-
tient after placement of a BT shunt for an unbalanced atrio-
ventricular canal defect. This patient died 5 days after
discharge. Because of the lack of adequate insurance cover-
age, this patient was unable to be discharged with a pulse
oximeter, and the patient had no immediate access to a pedi-
atric cardiologist in the location where the family resided.
No autopsy was performed.
Control group. S1P for HLHS. Four patients died after
S1P for HLHS in this group. Two patients died suddenly
at home. One died 28 days after discharge, having been ad-
mitted 3 weeks before with an episode of dehydration. The
other patient died at 5 months of age with a history of poor
compliance with follow-up. Neither patient had associated
chromosomal or other anomalies. Autopsies were not
performed.
There were 2 inpatient deaths in patients with HLHS and
pulmonary vein stenosis. One patient died after readmis-
sion and a surgical attempt at relief of the pulmonary ve-
nous obstruction, and the other patient died shortly after
readmission for severe cyanosis and pulmonary venous
obstruction.
Shunts. Four patients died suddenly at home after shunt op-
erations. One patient with heterotaxy syndrome died 2 days
after discharge. This patient’s hospital course was signifi-
cant for shunt thrombosis, requiring stenting of the shunt
before discharge. One international patient with pulmonary
atresia after placement of a BT shunt, died of unknown
cause 5 months after discharge. One patient with pulmonary
atresia and ventricular septal defect died at 5 months of age
after being home for 2 months. The final patient died after
shunt and DKS anastomosis for an interrupted aortic arch
and ventricular septal defect. This patient also had 22q
deletion.
Identification of Interstage Recurrent/Residual
Lesions Requiring Treatment
S1P. In the study group residual lesions identified after S1P
for HLHS included recurrent arch obstruction (n ¼ 6),
restrictive atrial communication (n ¼ 1), and severe right858 The Journal of Thoracic and Cardiovascular Surgventricular dysfunction (n¼ 5). In the control group lesions
identified included recurrent arch obstruction (n ¼ 7) and
left pulmonary artery stenosis (n¼ 1). The mean ages at de-
tection, admission, and treatment of these lesions were not
statistically different between the 2 groups (3.5  0.3 and
3.2  0.3 months, respectively). However, 11 (92%) of
12 patients in the study group were detected at the time of
the high-risk clinic visit or brought to our attention through
HSM, which allowed for planned intervention. Only 1 pa-
tient came to our institution as a semiurgent transport
from an outside hospital. Three of 5 patients who had dem-
onstrated severely decreased right ventricular function were
directly admitted from the high-risk clinic to our cardiac in-
tensive care unit and underwent cardiac catheterization.
One patient required angioplasty for then-identified recur-
rent arch obstruction, and the other 2 patients had no dis-
cernable anatomic lesion but had increased systemic
vascular resistance. Both patients had completion of their
S2P during that admission. In the control group 2 of 8 pa-
tients presented to an emergency department with clinical
deterioration manifesting as poor feeding and perfusion,
both of whom subsequently required arch angioplasty.
One patient not suspected of any hemodynamic distur-
bances had detection of a significant arch obstruction at
the time of pre-S2 catheterization and underwent angio-
plasty at that time.
Shunts. In the study group residual lesions identified after
shunt placements included shunt and pulmonary artery ste-
nosis (n ¼ 1), arch obstruction (n ¼ 1), failure to thrive
(n ¼ 1), and severe ventricular dysfunction (n ¼ 1). In the
control group lesions identified included shunt stenosis
(n ¼ 5), discontinuous pulmonary arteries (n ¼ 1), arch ob-
struction (n ¼ 1), and right pulmonary artery stenosis
(n ¼ 1). The mean age at detection, admission, and treat-
ment of these lesions was younger in the study group
(2.7  0.9 months) compared with that of control subjects
(6.6  0.6 months, P< .005). All residual lesions in the
study patients were detected at the time of the high-risk
clinic visit or brought to our attention through HSM. Two
of 4 patients were direct admissions from the high-risk
clinic to the cardiac intensive care unit. One patient
with pulmonary atresia/intact ventricular septum had severeery c October 2011
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increased lactate levels on admission to the cardiac inten-
sive care unit. It was decided to start this patient on cardio-
pulmonary support the same day. This patient underwent
successful bidirectional cavopulmonary anastomosis
(BDCPA) during that admission. The other patient, also
with PAT/intact ventricular septum, had presented to our
high-risk clinic with an oxygen saturation of 60% and
was taken to the cardiac catheterization laboratory for stent-
ing of both the shunt and left pulmonary artery.
In the control group the predominant lesion necessitat-
ing admission was shunt or pulmonary artery stenosis, oc-
curring in 6 of 8 patients. The mean age at presentation
was 6 months. All 6 patients presented with cyanosis,
and 2 of 6 patients presented to outside emergency depart-
ments and required emergency transport to our hospital.
Four of 6 patients were progressed semiurgently to
BDCPA. One patient underwent stent implantation into
the shunt, and 1 patient was electively scheduled for
BDCPA. One of 8 patients had discontinuous pulmonary
arteries detected at the time of pre-S2 catheterization,
which was performed at 9 months of age. This patient
had been previously lost to follow-up. He underwent
successful BDCPA with reinstitution of pulmonary artery
continuity.
DISCUSSION
The first quality improvement project undertaken by The
Joint Council on Congenital Heart Disease Quality Im-
provement Task Force8 was directed toward improvement
in the interstage quality of life for patients with HLHS be-
tween their S1P and S2P procedures. The concept of im-
provement in clinical outcomes through a reduction in
institutional and individual cardiology practice variability
is at the center of this project. Support for protocol-driven
management associated with improved hospital survival
and interstage survival is provided in many recent publica-
tions with regard to this fragile patient population.9 We
know from other high-risk endeavors that it is exactly this
checklist approach that is responsible for improvement in
outcomes. In our experience a high-risk program leads to
fewer interstage outpatient deaths and earlier detection of
important recurrent/residual lesions.
A critical component to the success of any home inter-
vention with high-risk patients is empowering the parent/
caregiver through education, repetition, and failsafe mech-
anisms. Parents must be enabled to contact their primary
cardiologists, the tertiary center, or both at any time with
a disturbance in the usual pattern of their infant. Hemody-
namic compromise might manifest simply as feeding intol-
erance. A high-risk program offers a direct line of
communication to a dedicated cardiac nurse practitioner
who they know and with whom they have regular telephone
contact. Any instruments we can provide to empower fam-The Journal of Thoracic and Cailies, whether the ability to call with a change in weight or
a change in oxygen saturation, are key components in the
success of HSM. Pulse oximetry and weight gain issues
are familiar to parents after stays in the intensive care
unit. Contact telephone numbers and printed materials
that clearly delineate the patient’s history and condition
are also important. In particular, this material is important
in the event of an emergency department visit or contact
with medical personnel not familiar with single-ventricle
physiology. The goal with this group of patients is to antic-
ipate and detect problems early, thereby avoiding emer-
gency department visits. The use of a database that is
easily accessible and continually monitored helps ensure
timely follow-up. On one occasion we used the Department
of Social Services when we detected repeated missed ap-
pointments. All of the abovemechanisms strive to minimize
the stress imposed on families caring for infants with com-
plex congenital heart disease.
In our experience minimizing the variation in care of
these infants during the interstage period is of critical im-
portance. This allows the team to provide anticipatory
care. There were procedural changes in our congenital heart
program that were a direct result of the high-risk program.
We now have a scheduled time for pre-S2 catheterizations
(3–4 months of age) for our patients with HLHS and
a scheduled time for S2P (4 months of age). This was ac-
complished by scheduling the patient at the time of the
high-risk visit for the catheterization and by the high-risk
team facilitating the scheduling of subsequent operations.
In the years before the high-risk program, palliated infants
were catheterized anywhere from 4 to 8 months after their
SIP, depending on individual practices. Not surprisingly,
the older shunted infants manifested with problems of shunt
stenosis and discontinuous pulmonary arteries. The timing
of progression to S2P should be institution dependent but
should be consistent and provide a failsafe mechanism
against loss of follow-up.
The ability to perform sedated echocardiography in a con-
trolled and monitored environment with a dedicated seda-
tion nurse and critical care physician gives the tertiary
center an advantage over the private cardiology office.
With few exceptions, sedated echocardiography provided
the details necessary to identify many of the recurrent/resid-
ual lesions in these patients.
Recurrent arch obstruction was the most common reason
for an interstage admission and catheter intervention in our
patients with HLHS. What is not quantifiable is the detri-
mental effect of prolonged arch obstruction on cardiac func-
tion over the course of the patient’s lifetime. In efforts to
preserve long-term function, it is logical to assume that ear-
lier detection and treatment is beneficial. For the palliated
patients with shunts followed in our high-risk program, re-
current/residual lesions were detected at a significantly
younger age. This suggests that a program such as thisrdiovascular Surgery c Volume 142, Number 4 859
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sions, leading to timely admission and treatment and possi-
bly increased interstage survival. In the control group
partial shunt occlusion was the most frequently identified
lesion requiring intervention, yet only 1 patient presented
with this problem in the study group. Perhaps with the ear-
lier timing of our pre-S2 catheterization and progression to
S2P there was less time for shunt occlusion to develop.
A high-risk program should be viewed as support for the
private cardiologist during the most critical interstage pe-
riod for these fragile patients. It should be designed to pro-
vide multidisciplinary care focused on medical, social,
nutritional, and developmental needs. Frequent communi-
cation between parents and high-risk personnel helps iden-
tify potential problems early before the need for emergency
care arises. Not uncommonly, our study patients had a lapse
in health insurance coverage during this interstage period.
This was relatively easy for our cardiac nurse practitioner
to identify and our social worker to remediate. In the control
group a lapse in insurance coverage might have contributed
to loss or delays in follow-up care.
Our institution now offers hybrid palliation to a select
group of patients with HLHS. Our first hybrid palliation
was in 2007, 1 year after the inception of our high-risk pro-
gram. All of our hybrid patients have been followed in our
high-risk program. For the purposes of this article, these pa-
tients were not included because of the lack of a comparison
group. Although beyond the scope of this discussion, it has
been our experience that these patients might benefit the
most from this type of intense interstage monitoring and
support. These patients require more frequent high-risk out-
patient evaluations. Although we have had no interstage
deaths in this select population to date, all of our hybrid pa-
tients have had at least 1 and often multiple interstage ad-
missions for catheter or surgical treatment of residual/
recurrent lesions.
Limitations
We were not able to follow all patients deemed eligible
for our high-risk program because participation was at the
discretion of the primary cardiologist. Our experience, in860 The Journal of Thoracic and Cardiovascular Surgpart, was a retrospective review, and our patient numbers
are small. This supports the multicenter efforts to reduce
the number of interstage mortalities in this fragile group
of patients.
CONCLUSIONS
It is possible for a congenital heart program to attain
nearly 0% interstage mortality in their most fragile infants
after palliative operations. The mechanism for decreasing
interstage attrition is multifactorial. We believe the key
components revolve around empowering caregivers
through education and failsafe mechanisms and enabling
the cardiac team to provide as much anticipatory care as
possible. The anticipatory care stems from minimizing var-
iations in care. In our experience standardized interstage
care for these infants allows for earlier detection and treat-
ment of residual lesions, which might result in a significant
reduction in morbidity and mortality.
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